• MK-2206 dihydrochloride: Redefining PI3K/Akt Pathway Inhibit

  2026-05-22

  Explore the advanced scientific applications of MK-2206 dihydrochloride as a selective Akt inhibitor, including its mechanistic role in apoptosis and angiogenesis research. This in-depth analysis highlights new insights for optimizing PI3K/Akt/mTOR signaling studies.

• E-4031: Precision hERG Potassium Channel Blocker in 3D Cardi

  2026-05-22

  Leverage E-4031’s selectivity for hERG potassium channels to model arrhythmias and QT prolongation in advanced 3D cardiac organoid systems. This guide details applied workflows, protocol optimization, and troubleshooting strategies to maximize data fidelity when translating bench research to high-content cardiac disease modeling.

• Tris(2-carboxyethyl) Phosphine Hydrochloride in Proteomic In

  2026-05-21

  Discover how Tris(2-carboxyethyl) phosphine hydrochloride (TCEP hydrochloride) is redefining proteomics and redox biochemistry. This in-depth analysis explores its mechanistic edge, advanced applications, and critical impact in light of new research.

• 3D Electrophysiology Mapping of Cardiac Organoids Using Shel

  2026-05-21

  This study introduces shell-shaped microelectrode arrays (MEAs) for high-resolution, spatiotemporal mapping of electrical activity in 3D cardiac organoids. By enabling pharmacological testing—including with hERG potassium channel blockers like E-4031—the platform provides powerful new capabilities for disease modeling and drug safety assessment.

• TUNEL Apoptosis Detection Kit: Streamlined DNA Fragmentation

  2026-05-20

  The TUNEL Apoptosis Detection Kit (DAB) from APExBIO advances apoptosis research with robust, direct DNA fragmentation detection across tissue sections and cultured cells. Its stepwise workflow, HRP-DAB chromogenic readout, and versatile adaptability deliver reproducible, publication-ready results—even in challenging experimental models.

• Artesunate: Mechanisms and Benchmarks in Cancer Research

  2026-05-20

  Artesunate, a semi-synthetic artemisinin derivative, demonstrates potent anticancer activity via AKT/mTOR pathway inhibition and induction of ferroptosis. Its defined solubility and stability profile, as documented by APExBIO, support robust in vitro applications in small cell lung carcinoma and esophageal squamous cell carcinoma models.

• Danazol in Endocrine Research: Applied Workflows and Solutio

  2026-05-19

  Danazol’s unique inhibition of steroidogenesis and LH suppression offers precise experimental control for endocrine and oncology studies. This guide translates the latest model-driven advances, including innovative use-cases in puberty research, into actionable protocols and troubleshooting strategies with APExBIO’s high-purity Danazol.

• Prestained Protein Marker: Triple Color Precision for SDS-PA

  2026-05-19

  The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) from APExBIO transforms routine and advanced SDS-PAGE and Western blotting with vivid multi-color bands and EDTA-free compatibility. Its design streamlines protein size verification and transfer monitoring, even in phosphoprotein and fluorescent imaging workflows.

• Selective Autophagy Regulates IRF3 for Balanced Interferon R

  2026-05-18

  Wu et al. reveal that selective autophagy, mediated by CALCOCO2/NDP52 and regulated by deubiquitinase PSMD14, controls the degradation and stability of transcription factor IRF3 in a virus load-dependent manner. This mechanism ensures precise type I interferon (IFN) production and immune suppression, advancing our understanding of antiviral innate immunity and the regulation of key transcription factors.

• Glabridin-Gold(I) Complex 6d Enhances Antitumor Immunity via

  2026-05-18

  This study introduces a novel glabridin-gold(I) complex (6d) as an immunomodulatory agent that simultaneously targets thioredoxin reductase and MAPK pathways. The research demonstrates that 6d synergistically enhances antitumor immunity in liver cancer models by promoting dendritic cell maturation and reducing immunosuppressive cell populations, offering a promising dual-inhibition strategy for future combination immunotherapies.

• CMA Decline Drives Age-Related Myopathy via Skeletal Muscle

  2026-05-17

  This study uncovers the critical role of chaperone-mediated autophagy (CMA) in maintaining skeletal muscle function and shows that age-driven decline in CMA leads to progressive myopathy through disrupted proteostasis and impaired calcium handling. The findings highlight new mechanistic links between autophagy, mitochondrial regulation, and muscle aging, with implications for therapeutic targeting of proteolytic systems.

• Tofacitinib (CP-690550, Tasocitinib): Reliable Immune Modula

  2026-05-16

  Explore how Tofacitinib (CP-690550, Tasocitinib) (SKU A4138) delivers reproducible inhibition of JAK/STAT pathways in immune cell assays, addressing persistent challenges in cytokine signaling blockade and functional phenotyping. This article presents scenario-driven, literature-backed solutions for optimizing cell viability and proliferation workflows, highlighting why APExBIO’s formulation is trusted by biomedical researchers.

• Antipyrine in CNS Research: Applied Protocols and Optimizati

  2026-05-15

  Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one) is the gold-standard reference for in vitro blood-brain barrier and pharmacokinetic studies, enabling reproducible and translational CNS research. This article details stepwise workflows, troubleshooting, and strategic advantages of APExBIO’s high-purity Antipyrine, with actionable insights from the latest BBB model innovations.

• 3D Shell MEAs Enable Advanced Electrophysiology in Cardiac O

  2026-05-15

  This study introduces programmable shell microelectrode arrays (MEAs) for high-resolution, three-dimensional mapping of electrical activity in human cardiac organoids. The technology addresses the longstanding challenge of capturing spatially resolved electrophysiological data in 3D tissues, enabling improved disease modeling and pharmacological testing.

• Targeting AR and ARv7 in TNBC: Enzalutamide's Impact on Meta

  2026-05-14

  This study demonstrates that both the androgen receptor (AR) and its splice variant ARv7 are associated with poor prognosis and increased metastasis in triple-negative breast cancer (TNBC) patients. Targeting AR/ARv7 with Enzalutamide and EPI-001 in vitro attenuates metastatic and epithelial-mesenchymal transition markers, suggesting a potential pathway for therapeutic intervention.

444 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page